In the News
Press Releases
Alzheon Presents Positive Results of ALZ-801 Clinical Studies that Lead to Advancement to Pivotal Phase 3 Study in Alzheimer’s Patients with APOE4/4 Homozygous Genotype
Pharmacokinetic and Safety Data from Phase 1b Studies with ALZ-801, an Optimized Prodrug of Tramiprosate, Presented at the Alzheimer's Association International Conference FRAMINGHAM, Mass., July 25, [...]
Alzheon Announces Efficacy Analyses of Prior Tramiprosate Phase 3 Studies Showing Clinically Meaningful Benefits on Key Clinical Endpoints in Alzheimer’s Disease Patients with APOE4 Genotype
Results Support Advancement of ALZ‐801 into Pivotal Clinical Studies in APOE4/4 Homozygous Subjects with Mild to Moderate Alzheimer’s Disease Data Presented at the 14th Annual International [...]
Alzheon Announces Presentations at Two Upcoming Investor Conferences
FRAMINGHAM, Mass., November 12, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, [...]
Alzheon Announces Efficacy Outcomes from Two Prior Tramiprosate Phase 3 Studies
Patients with Mild to Moderate Alzheimer’s Disease and APOE4/4 Genotype ShowedRobust and Sustained Efficacy on Cognitive and Functional Co‐Primary Outcomes over 78 weeks with Favorable Safety [...]
Alzheon Announces Initiation of Clinical Studies with ALZ‐801 Bridging to Pivotal Phase 3 Study in Alzheimer’s Disease
Phase 1b Multiple Dose‐Ranging Study and Tablet Bioequivalence Study Will Provide Clinical Dose and Tablet Formulation Data to Support ALZ‐801 Phase 3 Program FRAMINGHAM, Mass., November [...]
Alzheon Appoints Susan Abushakra, M.D., as Chief Medical Officer
FRAMINGHAM, Mass., September 9, 2015 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological [...]